

NLRP3 Inflammasome and Host Protection against Bacterial Infection

Jwa-Jin Kim and Eun-Kyeong Jo

Department of Microbiology and Infection Signaling Network Research Center, Chungnam National University School of Medicine, Daejeon, Korea

Received: 24 June 2013

Accepted: 20 August 2013

Address for Correspondence:

Eun-Kyeong Jo, MD

Department of Microbiology, and Infection Signaling Network Research Center, Chungnam National University School of Medicine, 266 Munhwa-ro, Jung-gu, Daejeon 301-747, Korea
Tel: +82.42-580-8243, Fax: +82.42-585-3686
E-mail: hayoungji@cnu.ac.kr

This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (No. 2007-0054932) at Chungnam National University, and by a grant of the Korea Healthcare Technology R&D Project, Ministry for Health, Welfare & Family Affairs, Republic of Korea (HI10C0573).

The inflammasome is a multi-protein complex that induces maturation of inflammatory cytokines interleukin (IL)-1 β and IL-18 through activation of caspase-1. Several nucleotide binding oligomerization domain-like receptor family members, including NLRP3, recognize unique microbial and danger components and play a central role in inflammasome activation. The NLRP3 inflammasome is critical for maintenance of homeostasis against pathogenic infections. However, inflammasome activation acts as a double-edged sword for various bacterial infections. When the IL-1 family of cytokines is secreted excessively, they cause tissue damage and extensive inflammatory responses that are potentially hazardous for the host. Emerging evidence has shown that diverse bacterial pathogens or their components negatively regulate inflammasome activation to escape the immune response. In this review, we discuss the current knowledge of the roles and regulation of the NLRP3 inflammasome during bacterial infections. Activation and regulation of the NLRP3 inflammasome should be tightly controlled to prevent virulence and pathology during infections. Understanding the roles and regulatory mechanisms of the NLRP3 inflammasome is essential for developing potential treatment approaches against pathogenic infections.

Key Words: NLRP3 Protein, Human; Bacteria; Infection; Inflammation; Host Defense; Pathology

INTRODUCTION

The inflammasomes are a group of cytosolic protein complexes that function as a molecular platform for caspase-1-dependent proteolytic maturation and secretion of interleukin (IL)-1 β and IL-18 (1-4). Of the members of the nucleotide binding oligomerization domain (NOD)-like receptor (NLR) inflammasomes, the nucleotide-binding domain and leucine-rich repeat protein 3 (NLRP3) inflammasome is the most extensively studied. Activation of the NLRP3 inflammasome in response to diverse pathogenic and endogenous stimuli leads to the assembly of protein components of the complex: the cytoplasmic innate receptor NLRP3, the adaptor apoptosis-associated speck-like protein containing a CARD (ASC), and the effector caspase-1 (1, 4, 5). The NLRP3 inflammasome is activated by two steps: a priming step is required to induce expression of both NLRP3 and pro-IL-1 β ; and a second step triggers assembly of the NLRP3 inflammasome after exposure to microbial toxins and ionophores or endogenous danger molecules (6, 7). In addition, the NLRP3 inflammasome is activated during infection of macrophages with various bacterial, viral, and fungal pathogens and is required for host immune defense to these pathogenic infections (6-8). The potent inflammatory activities of IL-1 β and IL-18 by in-

flammasome activation are pathogenic in NLRP3-associated autoinflammatory disorders (5, 9). Therefore, NLRP3 inflammasome activation is tightly controlled at multiple levels. NLRP3 inflammasome activation can lead to excessive inflammatory responses and cell death, which is potentially hazardous to host defense during a variety of bacterial infections, while numerous bacteria and their components can activate or modulate NLRP3 inflammasome activation. In this review, we will examine how the NLRP3 inflammasome is activated and contributes to host defense during diverse bacterial infections. We will further discuss current knowledge of the strategies by which various pathogenic bacterial virulence factors modulate the NLRP3 inflammasome.

THE MECHANISM OF NLRP3 INFLAMMASOME ACTIVATION

The innate immune system rapidly recognizes and provides an immediate host defense response to microbial and endogenous stimuli. The germ-line encoded pattern recognition receptors (PRRs) play an important role in recognition of pathogen- and danger-associated molecular patterns. Specific subsets of PRRs, NOD-like receptor (NLR) and the PYHIN protein

families, detect molecular patterns in the cytosol and activate the formation of supramolecular complexes, termed inflammasomes. The NLRP3 inflammasome, the best-characterized family member of inflammasomes, is a multi-protein complex composed of NLRP3, ASC, and caspase-1 (1-4).

The protein structure of NLRP3 contains an N-terminal pyrin domain (PYD), a central NACHT (*NAIP*, *CIITA*, *HET-E*, and *TPI*), and a C-terminal leucine-rich region (4). A recent study with high resolution structure analysis showed that NLRP3 has a specific disulfide bond between Cys-8 and Cys-108 that may participate in regulation of NLRP3 activity by reactive oxygen species (10). After sensing signals, the three components—NLRP3, ASC, and pro-caspase-1—assemble to form a typical multimeric inflammasome complex, which results in activation of caspase-1, leading to processing of pro-IL-1 β and pro-IL-18 to their mature, biologically active, forms (3-5). During this activation, the adaptor protein ASC, which contains an N-terminal PYD and a C-terminal caspase activation and recruitment domain (CARD), plays an important role in assembly of the NLRP3 inflammasome through its interaction with NLRP3 via a homotypic PYD interaction. Recent studies have reported that the ASC PYD domain is also required for its self-association, as well as interaction with NLRP3 (11).

A two-signal model has been proposed for activation of the NLRP3 inflammasome. The first signal mediates transcriptional activation of pro-IL-1 β and NLRP3 through recognition of ligands for toll-like receptors (TLRs), IL-1 receptor, and tumor necrosis factor (TNF) receptor. The second signal leads to inflammasome oligomerization and activation, thereby causing maturation and secretion of IL-1 β and IL-18. The second signal may include a variety of pathogen-associated molecular pattern molecules (PAMPs) or damage-associated molecular patterns (DAMPs) (2, 6, 9, 12). Several important second signals have been reported; i.e., plasma membrane disruption for bacterial toxins and ATP; internalization of particulate activators by phagocytosis (1); K⁺ efflux and pore formation by extracellular ATP or bacterial toxins (13); or lysosomal destabilization with release of protease cathepsin B into the cytoplasm by particulate activators including silica, alum, fibrillar amyloid- β protein, or uric acid crystals (1). A recent study has shown that liposomes trigger activation of the NLRP3 inflammasome through mitochondrial reactive oxygen species and calcium influx via the transient receptor potential melastatin 2 channel (14).

During infection, bacterial pathogen escape from the lysosome after phagocytosis is an important signal inducing NLRP3 inflammasome activation (15). However, activation of the NLRP3 inflammasome appears to be dependent on various cell types and stimuli. For example, the NLRP3 inflammasome can be spontaneously activated by primary stimulation of human monocytes, during which stimulation of certain PAMP and DAMP signals provide sufficient signals to trigger mature IL-1 β secre-

tion (16). The general concepts of NLRP3 inflammasome activation and the two-signal model are shown in Fig. 1.

Emerging evidence has also revealed involvement of other mechanisms/signaling molecules, beyond the core machinery of the inflammasome complex, in inflammasome activation. A recent study showed that double-stranded RNA-dependent protein kinase (PKR, also known as EIF2AK2) plays an important role in inflammasome activation through physical interaction with several inflammasome components, including NLRP3 (17). Another study showed that guanylate binding protein (GBP) 5, a member of the interferon (IFN)-inducible GBP family, can physically interact with the pyrin domain of NLRP3 and contributes to oligomerization of the NLRP3 inflammasome complex (18). To activate NLRP3 inflammasome, it was suggested that the adaptor ASC on mitochondria should be moved to NLRP3 on the endoplasmic reticulum (19, 20). A recent study proposed a spatial assembly model of microtubule-driven approximation between ASC and NLRP3, which depends on a low intracellular concentration of NAD⁺ and SIRT2-dependent deacetylation of microtubules (20). The NLRP3 inflammasome-activating signals trigger the recruitment of NLRP3 to mitochondria, and this is dependent on mitochondrial antiviral signaling protein (MAVS) (21), the mitochondrial outer membrane protein that was originally reported as a signaling adaptor leading the production of type 1 interferon (IFN) (22, 23). In addition, voltage-dependent anion channels (VDAC) is essential for NLRP3 inflammasome activation through the uptake of Ca²⁺ into the mitochondria from MAMs (19). The current model of NLRP3 inflammasome activation and its assembly is shown in Fig. 1.

BACTERIAL INFECTION AND NLRP3 INFLAMMASOME ACTIVATION

Diverse infectious microbes activate the NLRP3 inflammasome. In this section, we discuss several bacterial pathogens and their products that induce NLRP3 inflammasomes in vitro and in vivo (Fig. 2). Earlier studies showed that gram-positive *Staphylococcus aureus* or *Listeria monocytogenes*, but not *Salmonella typhimurium* or *Francisella tularensis*, require NLRP3 inflammasome activation (24). In addition, *Shigella flexneri* can cause NLRP3-dependent necrosis; i.e., pyronecrosis, in macrophages; however, this necrotic death is not caspase-1 and IL-1 β dependent (25). Other gram-negative enteropathogens, such as enterohemorrhagic *Escherichia coli* (EHEC) and *Citrobacter rodentium*, induce NLRP3 inflammasome activation in bone marrow-derived macrophages in a Toll-IL-1 receptor (TIR)-domain-containing adapter-inducing interferon- β (TRIF)-dependent pathway. Interestingly, TRIF plays an essential role in the activation of caspase-11 in NLRP3 inflammasome activation during gram-negative bacterial infection (26). Gram-negative diplococci *Neisseria gonorrhoeae* infection promotes NLRP3 in-




Fig. 1. Model of NLRP3 inflammasome activation. Activation of caspase-1 by the NLRP3 inflammasome depends a multi-signal process. Signal 1 occurs when IL-1R, TNF or a TLR ligand binds its cognate receptor resulting in the translocation of NF- κ B into the nucleus where expression of *Nlrp3*, *pro-Il1 β* , and *Il-18* are induced. Signal 2 involves the assembly of NLRP3 inflammasome complex resulting in the recruitment of adaptor molecule ASC and pro-caspase-1, to induce processing and secretion of cytokines IL-1 β and IL-18. So far, several pathways for NLRP3 inflammasome activation have been identified in bacterial infection. They include phagocytosis of certain pathogenic microbes leading to rupture of lysosomes, stimulation of P2X7R, and its opening of the pannexin-1 pore to increase potassium efflux and mitochondrial ROS. Recent studies have identified the new players, GBP5, MAVS, or VDAC, in NLRP3 inflammasome activation. In addition, microtubule-driven spatial arrangement of mitochondria was suggested to promote activation of the NLRP3 inflammasome. Nevertheless, the complete molecular mechanisms how NLRP3 inflammasome activation occurs have not been fully understood.

flammasome activation through activation of cathepsin B and leads to NLRP3-dependent monocytic cell death (27).

Although *Mycobacterium tuberculosis* (Mtb) resists inflammasome activation (28), the atypical mycobacterium *Mycobacterium abscessus* can induce the maturation and secretion of IL-1 β in human monocyte-derived macrophages (29). However, there are controversial results in Mtb-induced NLRP3 inflammasome activation. In human monocytes/macrophages, the *M. tuberculosis* protein ESAT-6 was reported to stimulate NLRP3 inflammasome by disrupting cell membranes and allowing of Ag85 to access cytosol (30). Moreover, recent studies have shown that murine microglia primed with conditioned media from cultures of macrophages infected with Mtb induce caspase-1 activation and IL-1 β secretion after Mtb stimulation in a NLRP3- and ASC-dependent manner, suggesting a role for microglia-leukocyte interactions in the pathogenesis of tuberculous meningitis (31). Interestingly, a recent study has shown that *Orientia*

tsutsugamushi, a pathogen causing scrub typhus, induces ASC inflammasome activation to secrete IL-1 β in macrophages; however, this was not dependent on NLRP3, NLRP4 or AIM2 (32). *Chlamydia pneumoniae*, a common respiratory pathogen in atypical pneumonia, induces maturation and secretion of IL-1 β in unprimed bone marrow-derived macrophages during productive infection. *C. pneumoniae*-dependent caspase-1 activation and IL-1 β maturation were dependent on NLRP3/ASC (33).

In addition, a variety of bacterial components induce NLRP3 inflammasome activation through diverse mechanisms. Several bacterial toxins; e.g., nigericin (*Streptomyces hygroscopicus*), valinomycin (several streptomyces strain), maitotoxin (*Gambierdiscus toxicus*), aerolysin (*Aeromonas hydrophila*) and listeriolysin O (*L. monocytogenes*), trigger the NLRP3 inflammasome pathway through pore formation and plasma membrane disruption, as mentioned above (24, 34).




Fig. 2. Microbial activation of the NLRP3 inflammasomes. Pathogenic microorganisms activate the NLRP3 inflammasomes through multiple agonists and pathways. Various bacteria or their products can activate NLRP3 inflammasome activation through different mechanisms. The detailed information of NLRP3 activation or modulation by bacteria and/or their factors is described in the text.

The β -hemolysin of group B streptococci, a frequent life-threatening systemic inflammation and meningitis, can induce secretion of IL-1 β , as well as pro-IL-1 β synthesis, in bone marrow-derived dendritic cells. Interestingly, the production of IL-1 β and pro-IL-1 β can be efficiently blocked by bafilomycin treatment, suggesting that group B streptococci-induced inflammasome activation is dependent on bacterial internalization and phagosomal acidification (35). In addition, the pneumolysin virulence factor of *S. pneumoniae* can induce the NLRP3 inflammasome, leading to enhanced secretion of cytokines, including IL-17A and IFN- γ (36). Recent studies have also reported that the *S. aureus* virulence factors α -, β -, and γ -hemolysin can activate the NLRP3 inflammasome during *S. aureus* pneumonia, although pulmonary injury induced by live *S. aureus* is not dependent on IL-1 β signaling (37). Moreover, *S. aureus* pore-forming toxin PVL activates the NLRP3 inflammasome and subsequent pyronecrosis (38).

A recent study showed that Td92, a surface protein of *Treponema denticola*, one of the major periodontopathogens, can induce NLRP3 inflammasome activation in macrophages through a direct interaction with the host cell membrane integrin $\alpha 5\beta 1$ (39). Moreover, the cholera toxin B of *Vibrio cholerae* can induce non-canonical NLRP3 inflammasome activation in a caspase-

11-dependent manner (40). The effector YopJ of *Yersinia pestis*, the causative agent of plague, also leads to activation of the NLRP3/ASC/caspase-1 inflammasome in macrophages through a mechanism dependent on K⁺ efflux (41). Bacterial mRNA released from the lysosome can be sensed by NLRP3 inflammasome in the cytosol through detection of a special class of viability-associated PAMPs (42). The lipooligosaccharide structure of *N. gonorrhoeae* potentially activates the NLRP3 signaling system, suggesting that the lipooligosaccharide structure is involved in the pathogenesis of gonococcal infections (27). Accumulated knowledge of bacterial pathogens, their components, and the NLRP3 inflammasome activation will evoke a new avenue for understanding the pathogenesis, and/or developing potential strategies to treat, bacterial infections.

THE PROTECTIVE ROLES OF NLRP3 INFLAMMASOME ACTIVATION IN BACTERIAL INFECTION

Extensive research has revealed that NLRP3 inflammasome activation contributes to host defense against numerous bacterial infections. Mice lacking NLRP3, ASC, or caspase-1 were more susceptible to group B streptococcal infection than wild-type

mice, suggesting a critical role for the NLRP3 inflammasome in successful anti-streptococcal responses (35). Streptococcal pneumolysin-induced NLRP3 inflammasome activation contributes to protective immunity through induction of IL-17A and IFN- γ secretion against respiratory infection with *S. pneumoniae* (36). Using a murine model of melioidosis, previous studies showed that the inflammasome components ASC, caspase-1, and NLRP3 are critical for host defense against lung infection with *Burkholderia pseudomallei* through synthesis and secretion of IL-1 β (43). In addition, mice lacking the inflammasome components Nlrp3, Nlrc4, and caspase-1 exhibited increased susceptibility to *Citrobacter rodentium* infection, which is similar to human infection with enteropathogenic and enterohemorrhagic *E. coli* (44). In addition, IL-1 β - and IL-18-null mice also had increased bacterial burdens and showed an exacerbated pattern of histopathology (44). Moreover, mice lacking both Nlrp3 and Nlrp4 are highly susceptible to *S. typhimurium* infection, suggesting the redundant roles of the two NLRs in host innate defense against *Salmonella* infection (45). However, a recent study has shown that caspase-11—not NLRP3, NLRC4, or ASC—is critical for host defense and enhanced clearance of bacteria using a *S. typhimurium* mutant strain (*sifA*), which can aberrantly enter the host cell cytosol (46).

During chronic infections caused by Mtb, inflammasome activation and generation of IL-1 β may play a dual role in both innate immune defense and inflammatory pathogenic responses. Although AIM2 inflammasomes appear to be protective against Mtb infection (47), NLRP3 inflammasome activation is associated with the immunopathology of tuberculosis, rather than host defense against Mtb infection (48, 49). In *Mycobacterium kansasii* infection, NLRP3 inflammasome activation and secreted IL-1 β derived from caspase-1 activation play an important role in host defense and restriction of intracellular *M. kansasii* (50). Moreover, Gbp5-deficient mice are defective in caspase-1 cleavage and maturation of IL-1 β /IL-18 in vitro and impaired host defense against listerial infection in vivo (18).

In this context, a recent study demonstrated that a network of immune cell populations spatially organized in lymph nodes can efficiently interact with lymphatic sinus-lining sentinel macrophages, and respond rapidly to inflammasome-induced IL-18 produced by these phagocytes, leading to lymphoid cell IFN- γ secretion, which limits systemic spread of the pathogens (51). Thus, inflammasome activation is important for a local and acute innate immune response to limit deep invasion of the lymph nodes by pathogenic bacteria (51).

THE PATHOGENIC ROLES OF NLRP3 INFLAMMASOME ACTIVATION IN BACTERIAL INFECTION

Although the inflammasome activation plays a key role in limit-

ing the spread of an invading pathogen, it can be deleterious due to tissue damage associated with chronic inflammatory responses. When inflammasome activation functions improperly or is uncontrolled, chronic inflammation may develop into various immune disorders, including Crohn's disease, ulcerative colitis, or arthritis (52). IL-1 β and IL-18 are potent proinflammatory cytokines that are required for host defense against diverse infections, and simultaneously are involved in various inflammatory pathologies. In addition to processing IL-1 β , inflammasome activation often results in the caspase-1-mediated pyroptotic form of cell death, which leads to bacterial exposure, efficient uptake, and killing by neutrophils (53). However, repeated rounds of pyroptosis can lead to severe inflammatory changes and significant damage to host tissues, particularly in the absence of downstream killing by neutrophils (53). TRIF signaling is essential for NLRP3 inflammasome activation by several gram-negative bacteria, and in detrimental inflammation associated with enteric infections (26).

Earlier studies showed that IL-1 secreted by epithelial cells after *Chlamydia trachomatis* infection is associated with tissue damage to the Fallopian tube, potentially leading to infertility (54). It was also reported that *C. trachomatis* infection of human monocytes triggers secretion of IL-1 β through NLRP3 inflammasome activation, which induces an inflammatory response to this pathogen (55). In genital infection with *Chlamydia muridarum*, mice lacking NLRP3, NLRC4, and ASC showed no reduction in oviduct pathology compared with control mice, suggesting a limited role for the inflammasome pathway during genital chlamydial infection (56).

In *Helicobacter pylori* infection, IL-1 β is primarily proinflammatory, whereas IL-18 counteracts the inflammatory responses induced by IL-1 β and Th17 (57). Interestingly, two caspase-1 substrates act together to achieve balanced control of *Helicobacter* infection and avoid excessive gastric pathology (57). The gram-negative spirochete, *Borrelia burgdorferi*, a pathogen of chronic Lyme disease-associated arthritis, activates the inflammasome in a manner dependent on ASC and caspase-1, but not NLRP3 (58, 59). In addition, IL-1 is a major pathogenic mediator of Lyme arthritis and is not required for control of Lyme borreliosis in murine models (59, 60).

Activation of the NLRC4 inflammasome by the flagella of *Pseudomonas aeruginosa* is deleterious to bacterial clearance in acute pneumonia and associated with increased cell death (61). In corneal infection with *P. aeruginosa*, caspase-1 deficiency leads to inhibition of cytokine and chemokine production, and reduced infiltration of polymorphonuclear leukocytes, suppressing corneal damage and inflammation (62). These studies suggest that targeting the inflammasome limits the pathological responses during *P. aeruginosa* infection.

In *Mycobacterium marinum* infection, the ESX-1 (type VII) secretion system, a major virulence determinant, promotes NL-

RP3 and the ASC-dependent inflammasome. However, NLRP3 inflammasome activation by *M. marinum* is responsible for host-detrimental effects without restricting bacterial growth (48). Similarly, the ESX-1 secretion system and ESAT-6 proteins induce NLRP3 inflammasome activation, which leads to necrotic death of THP-1 human macrophages via a Syk tyrosine kinase (63). In vivo, an Mtb aerosol infection study indicated that neither Nlrp3 nor Casp-1 null mice show any differences in pulmonary bacterial burden or long-term survival, when compared with wild-type mice (64). However, ASC appears to be important in host protection against chronic Mtb infection because ASC-deficient mice exhibit reduced survival and defective granuloma formation (64). Moreover, killed Mtb, the immunostimulatory component in complete Freund's adjuvant, promotes experimental autoimmune encephalomyelitis through activation of the inflammasome complex in dendritic cells and increased IL-17 production by CD4 and $\gamma\delta$ T cells (65). These findings suggest that modulation of inflammasome activation may prevent tissue damage and host death in response to a variety of bacterial infections.

MODULATION OF NLRP3 INFLAMMASOME ACTIVATION BY PATHOGENIC BACTERIA

Evidence of manipulation of inflammasome activation by bacterial pathogens has accumulated. Bacteria use diverse strategies to hijack or manipulate inflammasome activation in host cells (66). Several bacterial proteins that modulate NLRP3 inflammasome activation for immune evasion have been described. Earlier studies indicated that *P. aeruginosa* ExoS, a type III effector protein, negatively regulates caspase-1-dependent IL-1 β maturation through a mechanism dependent on its ADP-ribosyltransferase activity (67). In addition, *Yersinia* YopE and YopT prevent the activation of caspase-1 through inhibitory effects on Rac1 (68). The *Yersinia* type III secreted effector protein, YopK, can inhibit inflammasome activation through interaction with the T3SS translocon (69). Detection of the *Yersinia* type III secretion system (T3SS) by NLRP3 and NLRC4 induces the assembly of inflammasomes, and promotes bacterial clearance (69); YopK-mediated inhibition of inflammasome activation may have detrimental effects on host defense.

In addition, *Legionella pneumophila* can manipulate ASC levels to modulate inflammasome and NF- κ B pathway activation, thus evading immune evasion and promoting growth (70). When ASC was over-expressed in cells to maintain constant levels of protein during infection, caspase-1 activation and restriction of *Legionella* growth resulted (70). The zinc metalloprotease Zmp1 of Mtb is involved in the prevention of inflammasome activation by Mtb. Zmp1-deleted Mtb enhances the secretion of IL-1 β through inflammasome activation, which plays a role in Mtb phagosomal maturation and enhancement

of mycobacterial clearance in murine aerosol-infection models (28). The *Francisella tularensis* RipA protein inhibits secretion of IL-1 β , IL-18, and TNF- α by macrophages to escape from host immunity, and an *F. tularensis* ripA-deletion mutant (*LVS Δ ripA*) induced higher levels of inflammatory cytokines in animals (71). Collectively, these data demonstrate that a class of bacterial components modulates inflammasome recognition and assembly to evade the host immune system and promote bacterial survival within host cells/tissues.

CONCLUSION

NLRP3 inflammasome activation is crucial for recognition of cytosolic pathogenic microbes and allows the host to induce an appropriate protective innate immune response. A two-signal theory of triggering NLRP3 inflammasome assembly and activation has been proposed. However, evidence of activation or regulation of the inflammasome complex by other mechanisms/molecules has accumulated. Interestingly, many bacteria and their products can manipulate and/or activate the NLRP3 inflammasome complex. Future studies will identify additional host molecules or bacterial components that activate the inflammasome pathway.

It is clear that NLRP3 inflammasome activation contributes to host defense during a variety of bacterial infections. However, chronic inflammation accompanied by dysregulated inflammasome activation during persistent infection may result in detrimental effects and immunopathologies. In addition, many pathogenic bacteria subvert the NLRP3 inflammasome pathways, often through inhibition of, or interaction with, the inflammasome core machinery by virulence factors. In future research, additional virulence factors and mechanisms by which successful microbial pathogens modulate host inflammasome pathways will be clarified. Current knowledge of inflammasome activation or regulation by pathogens or their components must be expanded using appropriate genetic and/or animal models. Understanding how pathogens subvert host inflammasome signaling pathways will contribute to development of interventions to control bacterial infection and provide protective innate immunity to the host.

DISCLOSURE

The authors have no conflicts of interest to disclose.

REFERENCES

1. Cassel SL, Joly S, Sutterwala FS. The NLRP3 inflammasome: a sensor of immune danger signals. *Semin Immunol* 2009; 21: 194-8.
2. Franchi L, Eigenbrod T, Muñoz-Planillo R, Núñez G. The inflammasome: a caspase-1-activation platform that regulates immune responses and

- disease pathogenesis. *Nat Immunol* 2009; 10: 241-7.
3. Martinon F, Mayor A, Tschopp J. *The inflammasomes: guardians of the body. Annu Rev Immunol* 2009; 27: 229-65.
 4. Latz E. *The inflammasomes: mechanisms of activation and function. Curr Opin Immunol* 2010; 22: 28-33.
 5. Agostini L, Martinon F, Burns K, McDermott MF, Hawkins PN, Tschopp J. *NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity* 2004; 20: 319-25.
 6. Lamkanfi M, Dixit VM. *Inflammasomes: guardians of cytosolic sanctity. Immunol Rev* 2009; 227: 95-105.
 7. Tschopp J, Schroder K. *NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production? Nat Rev Immunol* 2010; 10: 210-5.
 8. Hise AG, Tomalka J, Ganesan S, Patel K, Hall BA, Brown GD, Fitzgerald KA. *An essential role for the NLRP3 inflammasome in host defense against the human fungal pathogen Candida albicans. Cell Host Microbe* 2009; 5: 487-97.
 9. Yang CS, Shin DM, Jo EK. *The role of NLR-related protein 3 inflammasome in host defense and inflammatory diseases. Int Neurobiol J* 2012; 16: 2-12.
 10. Bae JY, Park HH. *Crystal structure of NALP3 protein pyrin domain (PYD) and its implications in inflammasome assembly. J Biol Chem* 2011; 286: 39528-36.
 11. Vajjhala PR, Mirams RE, Hill JM. *Multiple binding sites on the pyrin domain of ASC protein allow self-association and interaction with NLRP3 protein. J Biol Chem* 2012; 287: 41732-43.
 12. Gombault A, Baron L, Couillin I. *ATP release and purinergic signaling in NLRP3 inflammasome activation. Front Immunol* 2012; 3: 414.
 13. Pelegrin P, Surprenant A. *Pannexin-1 couples to maitotoxin- and nigericin-induced interleukin-1beta release through a dye uptake-independent pathway. J Biol Chem* 2007; 282: 2386-94.
 14. Zhong Z, Zhai Y, Liang S, Mori Y, Han R, Sutterwala FS, Qiao L. *TRPM2 links oxidative stress to NLRP3 inflammasome activation. Nat Commun* 2013; 4: 1611.
 15. Vladimer GI, Marty-Roix R, Ghosh S, Weng D, Lien E. *Inflammasomes and host defenses against bacterial infections. Curr Opin Microbiol* 2013; 16: 23-31.
 16. Netea MG, Nold-Petry CA, Nold MF, Joosten LA, Opitz B, van der Meer JH, van de Veerdonk FL, Ferwerda G, Heinhuis B, Devesa I, et al. *Differential requirement for the activation of the inflammasome for processing and release of IL-1beta in monocytes and macrophages. Blood* 2009; 113: 2324-35.
 17. Lu B, Nakamura T, Inouye K, Li J, Tang Y, Lundbäck P, Valdes-Ferrer SI, Olofsson PS, Kalb T, Roth J, et al. *Novel role of PKR in inflammasome activation and HMGB1 release. Nature* 2012; 488: 670-4.
 18. Shenoy AR, Wellington DA, Kumar P, Kassa H, Booth CJ, Cresswell P, MacMicking JD. *GBP5 promotes NLRP3 inflammasome assembly and immunity in mammals. Science* 2012; 336: 481-5.
 19. Zhou R, Yazdi AS, Menu P, Tschopp J. *A role for mitochondria in NLRP3 inflammasome activation. Nature* 2011; 469: 221-5.
 20. Misawa T, Takahama M, Kozaki T, Lee H, Zou J, Saitoh T, Akira S. *Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome. Nat Immunol* 2013; 14: 454-60.
 21. Subramanian N, Natarajan K, Clatworthy MR, Wang Z, Germain RN. *The adaptor MAVS promotes NLRP3 mitochondrial localization and inflammasome activation. Cell* 2013; 153: 348-61.
 22. Kawai T, Takahashi K, Sato S, Coban C, Kumar H, Kato H, Ishii KJ, Takeuchi O, Akira S. *IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat Immunol* 2005; 6: 981-8.
 23. Meylan E, Curran J, Hofmann K, Moradpour D, Binder M, Bartenschlager R, Tschopp J. *Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature* 2005; 437: 1167-72.
 24. Mariathasan S, Weiss DS, Newton K, McBride J, O'Rourke K, Roose-Girma M, Lee WP, Weinrauch Y, Monack DM, Dixit VM. *Cryopyrin activates the inflammasome in response to toxins and ATP. Nature* 2006; 440: 228-32.
 25. Willingham SB, Bergstralh DT, O'Connor W, Morrison AC, Taxman DJ, Duncan JA, Barnoy S, Venkatesan MM, Flavell RA, Deshmukh M, et al. *Microbial pathogen-induced necrotic cell death mediated by the inflammasome components CIAS1/cryopyrin/NLRP3 and ASC. Cell Host Microbe* 2007; 2: 147-59.
 26. Rathinam VA, Vanaja SK, Waggoner L, Sokolovska A, Becker C, Stuart LM, Leong JM, Fitzgerald KA. *TRIF licenses caspase-11-dependent NLRP3 inflammasome activation by gram-negative bacteria. Cell* 2012; 150: 606-19.
 27. Duncan JA, Gao X, Huang MT, O'Connor BP, Thomas CE, Willingham SB, Bergstralh DT, Jarvis GA, Sparling PF, Ting JP. *Neisseria gonorrhoeae activates the proteinase cathepsin B to mediate the signaling activities of the NLRP3 and ASC-containing inflammasome. J Immunol* 2009; 182: 6460-9.
 28. Master SS, Rampini SK, Davis AS, Keller C, Ehlers S, Springer B, Timmins GS, Sander P, Deretic V. *Mycobacterium tuberculosis prevents inflammasome activation. Cell Host Microbe* 2008; 3: 224-32.
 29. Lee HM, Yuk JM, Kim KH, Jang J, Kang G, Park JB, Son JW, Jo EK. *Mycobacterium abscessus activates the NLRP3 inflammasome via Dectin-1-Syk and p62/SQSTM1. Immunol Cell Biol* 2012; 90: 601-10.
 30. Mishra BB, Moura-Alves P, Sonawane A, Hacoheh N, Griffiths G, Moita LF, Anes E. *Mycobacterium tuberculosis protein ESAT-6 is a potent activator of the NLRP3/ASC inflammasome. Cell Microbiol* 2010; 12: 1046-63.
 31. Lee HM, Kang J, Lee SJ, Jo EK. *Microglial activation of the NLRP3 inflammasome by the priming signals derived from macrophages infected with mycobacteria. Glia* 2013; 61: 441-52.
 32. Koo JE, Hong HJ, Dearth A, Kobayashi KS, Koh YS. *Intracellular invasion of Orientia tsutsugamushi activates inflammasome in asc-dependent manner. PLoS One* 2012; 7: e39042.
 33. He X, Mekasha S, Mavrogiorgos N, Fitzgerald KA, Lien E, Ingalls RR. *Inflammation and fibrosis during Chlamydia pneumoniae infection is regulated by IL-1 and the NLRP3/ASC inflammasome. J Immunol* 2010; 184: 5743-54.
 34. Gurcel L, Abrami L, Girardin S, Tschopp J, van der Goot FG. *Caspase-1 activation of lipid metabolic pathways in response to bacterial pore-forming toxins promotes cell survival. Cell* 2006; 126: 1135-45.
 35. Costa A, Gupta R, Signorino G, Malara A, Cardile F, Biondo C, Midiri A, Galbo R, Trieu-Cuot P, Papasergi S, et al. *Activation of the NLRP3 inflammasome by group B streptococci. J Immunol* 2012; 188: 1953-60.
 36. McNeela EA, Burke A, Neill DR, Baxter C, Fernandes VE, Ferreira D, Smeaton S, El-Rachkidy R, McLoughlin RM, Mori A, et al. *Pneumolysin activates the NLRP3 inflammasome and promotes proinflammatory cy-*

- tokines independently of *TLR4*. *PLoS Pathog* 2010; 6: e1001191.
37. Kebaier C, Chamberland RR, Allen IC, Gao X, Broglie PM, Hall JD, Jانيا C, Doerschuk CM, Tilley SL, Duncan JA. *Staphylococcus aureus* α -hemolysin mediates virulence in a murine model of severe pneumonia through activation of the NLRP3 inflammasome. *J Infect Dis* 2012; 205: 807-17.
 38. Holzinger D, Gieldon L, Mysore V, Nippe N, Taxman DJ, Duncan JA, Broglie PM, Marketon K, Austermann J, Vogl T, et al. *Staphylococcus aureus* Panton-Valentine leukocidin induces an inflammatory response in human phagocytes via the NLRP3 inflammasome. *J Leukoc Biol* 2012; 92: 1069-81.
 39. Jun HK, Lee SH, Lee HR, Choi BK. *Integrin $\alpha 5\beta 1$* activates the NLRP3 inflammasome by direct interaction with a bacterial surface protein. *Immunity* 2012; 36: 755-68.
 40. Kayagaki N, Warming S, Lamkanfi M, Vande Walle L, Louie S, Dong J, Newton K, Qu Y, Liu J, Heldens S, et al. *Non-canonical inflammasome activation targets caspase-11*. *Nature* 2011; 479: 117-21.
 41. Zheng Y, Lilo S, Brodsky IE, Zhang Y, Medzhitov R, Marcu KB, Bliska JB. *A Yersinia effector with enhanced inhibitory activity on the NF- κ B pathway activates the NLRP3/ASC/caspase-1 inflammasome in macrophages*. *PLoS Pathog* 2011; 7: e1002026.
 42. Sander LE, Davis MJ, Boekschoten MV, Amsen D, Dascher CC, Ryffel B, Swanson JA, Müller M, Blander JM. *Detection of prokaryotic mRNA signifies microbial viability and promotes immunity*. *Nature* 2011; 474: 385-9.
 43. Ceballos-Olvera I, Sahoo M, Miller MA, Del Barrio L, Re F. *Inflammasome-dependent pyroptosis and IL-18 protect against Burkholderia pseudomallei lung infection while IL-1 β is deleterious*. *PLoS Pathog* 2011; 7: e1002452.
 44. Liu Z, Zaki MH, Vogel P, Gurung P, Finlay BB, Deng W, Lamkanfi M, Kanneganti TD. *Role of inflammasomes in host defense against Citrobacter rodentium infection*. *J Biol Chem* 2012; 287: 16955-64.
 45. Broz P, Newton K, Lamkanfi M, Mariathasan S, Dixit VM, Monack DM. *Redundant roles for inflammasome receptors NLRP3 and NLRC4 in host defense against Salmonella*. *J Exp Med* 2010; 207: 1745-55.
 46. Aachoui Y, Leaf IA, Hagar JA, Fontana MF, Campos CG, Zak DE, Tan MH, Cotter PA, Vance RE, Aderem A, et al. *Caspase-11 protects against bacteria that escape the vacuole*. *Science* 2013; 339: 975-8.
 47. Saiga H, Kitada S, Shimada Y, Kamiyama N, Okuyama M, Makino M, Yamamoto M, Takeda K. *Critical role of AIM2 in Mycobacterium tuberculosis infection*. *Int Immunol* 2012; 24: 637-44.
 48. Carlsson F, Kim J, Dumitru C, Barck KH, Carano RA, Sun M, Diehl L, Brown EJ. *Host-detrimental role of Esx-1-mediated inflammasome activation in mycobacterial infection*. *PLoS Pathog* 2010; 6: e1000895.
 49. Mishra BB, Rathinam VA, Martens GW, Martinot AJ, Komfeld H, Fitzgerald KA, Sasseti CM. *Nitric oxide controls the immunopathology of tuberculosis by inhibiting NLRP3 inflammasome-dependent processing of IL-1 β* . *Nat Immunol* 2013; 14: 52-60.
 50. Chen CC, Tsai SH, Lu CC, Hu ST, Wu TS, Huang TT, Saïd-Sadier N, Ojcius DM, Lai HC. *Activation of an NLRP3 inflammasome restricts Mycobacterium kansasii infection*. *PLoS One* 2012; 7: e36292.
 51. Kastenmüller W, Torabi-Parizi P, Subramanian N, Lämmermann T, Germain RN. *A spatially-organized multicellular innate immune response in lymph nodes limits systemic pathogen spread*. *Cell* 2012; 150: 1235-48.
 52. Chilton PM, Embry CA, Mitchell TC. *Effects of differences in lipid A structure on TLR4 pro-inflammatory signaling and inflammasome activation*. *Front Immunol* 2012; 3: 154.
 53. Miao EA, Leaf IA, Treuting PM, Mao DP, Dors M, Sarkar A, Warren SE, Wewers MD, Aderem A. *Caspase-1-induced pyroptosis is an innate immune effector mechanism against intracellular bacteria*. *Nat Immunol* 2010; 11: 1136-42.
 54. Hvid M, Baczynska A, Deleuran B, Fedder J, Knudsen HJ, Christiansen G, Birkelund S. *Interleukin-1 is the initiator of Fallopian tube destruction during Chlamydia trachomatis infection*. *Cell Microbiol* 2007; 9: 2795-803.
 55. Abdul-Sater AA, Saïd-Sadier N, Padilla EV, Ojcius DM. *Chlamydial infection of monocytes stimulates IL-1beta secretion through activation of the NLRP3 inflammasome*. *Microbes Infect* 2010; 12: 652-61.
 56. Nagarajan UM, Sikes JD, Yeruva L, Prantner D. *Significant role of IL-1 signaling, but limited role of inflammasome activation, in oviduct pathology during Chlamydia muridarum genital infection*. *J Immunol* 2012; 188: 2866-75.
 57. Hitzler I, Sayi A, Kohler E, Engler DB, Koch KN, Hardt WD, Müller A. *Caspase-1 has both proinflammatory and regulatory properties in Helicobacter infections, which are differentially mediated by its substrates IL-1 β and IL-18*. *J Immunol* 2012; 188: 3594-602.
 58. Oosting M, van de Veerdonk FL, Kanneganti TD, Sturm P, Verschuereen I, Berende A, van der Meer JW, Kullberg BJ, Netea MG, Joosten LA. *Borrelia species induce inflammasome activation and IL-17 production through a caspase-1-dependent mechanism*. *Eur J Immunol* 2011; 41: 172-81.
 59. Oosting M, Buffen K, Malireddi SR, Sturm P, Verschuereen I, Koenders MI, van de Veerdonk FL, van der Meer JW, Netea MG, Kanneganti TD, et al. *Murine Borrelia arthritis is highly dependent on ASC and caspase-1, but independent of NLRP3*. *Arthritis Res Ther* 2012; 14: R247.
 60. Liu N, Belperron AA, Booth CJ, Bockenstedt LK. *The caspase 1 inflammasome is not required for control of murine Lyme borreliosis*. *Infect Immun* 2009; 77: 3320-7.
 61. Cohen TS, Prince AS. *Activation of inflammasome signaling mediates pathology of acute P: aeruginosa pneumonia*. *J Clin Invest* 2013; 123: 1630-7.
 62. Thakur A, Barrett RP, McClellan S, Hazlett LD. *Regulation of Pseudomonas aeruginosa corneal infection in IL-1 beta converting enzyme (ICE, caspase-1) deficient mice*. *Curr Eye Res* 2004; 29: 225-33.
 63. Wong KW, Jacobs WR Jr. *Critical role for NLRP3 in necrotic death triggered by Mycobacterium tuberculosis*. *Cell Microbiol* 2011; 13: 1371-84.
 64. McElvania Tekippe E, Allen IC, Hulseberg PD, Sullivan JT, McCann JR, Sandor M, Braunstein M, Ting JP. *Granuloma formation and host defense in chronic Mycobacterium tuberculosis infection requires PYCARD/ASC but not NLRP3 or caspase-1*. *PLoS One* 2010; 5: e12320.
 65. Lalor SJ, Dungan LS, Sutton CE, Basdeo SA, Fletcher JM, Mills KH. *Caspase-1-processed cytokines IL-1beta and IL-18 promote IL-17 production by gammadelta and CD4 T cells that mediate autoimmunity*. *J Immunol* 2011; 186: 5738-48.
 66. Rathinam VA, Vanaja SK, Fitzgerald KA. *Regulation of inflammasome signaling*. *Nat Immunol* 2012; 13: 333-2.
 67. Galle M, Schotte P, Haegman M, Wullaert A, Yang HJ, Jin S, Beyaert R. *The Pseudomonas aeruginosa type III secretion system plays a dual role in the regulation of caspase-1 mediated IL-1beta maturation*. *J Cell Mol Med* 2008; 12: 1767-76.
 68. Schotte P, Denecker G, Van Den Broeke A, Vandenabeele P, Cornelis

- GR, Beyaert R. *Targeting Rac1 by the Yersinia effector protein YopE inhibits caspase-1-mediated maturation and release of interleukin-1beta.* *J Biol Chem* 2004; 279: 25134-42.
69. Brodsky IE, Palm NW, Sadanand S, Ryndak MB, Sutterwala FS, Flavell RA, Bliska JB, Medzhitov R. *A Yersinia effector protein promotes virulence by preventing inflammasome recognition of the type III secretion system.* *Cell Host Microbe* 2010; 7: 376-87.
70. Abdelaziz DH, Gavrilin MA, Akhter A, Caution K, Kotrange S, Khweek AA, Abdulrahman BA, Grandhi J, Hassan ZA, Marsh C, et al. *Apoptosis-associated speck-like protein (ASC) controls Legionella pneumophila infection in human monocytes.* *J Biol Chem* 2011; 286: 3203-8.
71. Huang MT, Mortensen BL, Taxman DJ, Craven RR, Taft-Benz S, Kijek TM, Fuller JR, Davis BK, Allen IC, Brickey WJ, et al. *Deletion of ripA alleviates suppression of the inflammasome and MAPK by Francisella tularensis.* *J Immunol* 2010; 185: 5476-85.